Anavex Life Sciences (AVXL) EBITDA (2016 - 2025)
Anavex Life Sciences (AVXL) posted EBITDA of -$5.7 million for Q4 2025, up 47.78% sequentially from -$10.8 million in Q3 2025, and up 58.34% YoY from -$3.6 million in Q4 2024.
Anavex Life Sciences (AVXL) EBITDA (2016 - 2025) Analysis & Trends
Anavex Life Sciences has reported EBITDA for 10 years, with the latest figure at -$5.7 million in Q4 2025.
- Quarterly EBITDA rose 58.34% year-over-year to -$5.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$43.5 million (up 21.08% YoY) and the FY2025 annual result came in at -$51.4 million, up 2.78% from the prior year.
- EBITDA advanced to -$5.7 million in Q4 2025 per AVXL's latest filing, from -$10.8 million in the prior quarter.
- Over five years, EBITDA peaked at $195.1 million in Q2 2021 and troughed at -$15.4 million in Q4 2022.
- A 5-year average of $11.1 million and a median of -$12.6 million in 2024 frame the typical range for EBITDA.
- The widest YoY moves for EBITDA: up 4315.69% in 2021, down 184.78% in 2021.
- Over 5 years, EBITDA stood at -$11.7 million in 2021, then sank by 31.22% to -$15.4 million in 2022, then climbed by 26.04% to -$11.4 million in 2023, then fell by 19.46% to -$13.6 million in 2024, then surged by 58.34% to -$5.7 million in 2025.
- According to Business Quant data, EBITDA over the past three periods registered -$5.7 million, -$10.8 million, and -$14.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Anavex Life Sciences | 298.40 Mn | 166.65 Mn | - | -5.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.66 Mn |
| Sep 30, 2025 | -10.84 Mn |
| Jun 30, 2025 | -14.46 Mn |
| Mar 31, 2025 | -12.51 Mn |
| Dec 31, 2024 | -13.59 Mn |
| Sep 30, 2024 | -14.27 Mn |
| Jun 30, 2024 | -14.60 Mn |
| Mar 31, 2024 | -12.62 Mn |
| Dec 31, 2023 | -11.38 Mn |
| Sep 30, 2023 | -12.66 Mn |
| Jun 30, 2023 | -13.53 Mn |
| Mar 31, 2023 | -14.19 Mn |
| Dec 31, 2022 | -15.38 Mn |
| Sep 30, 2022 | -15.28 Mn |
| Jun 30, 2022 | -12.46 Mn |
| Mar 31, 2022 | -11.52 Mn |
| Dec 31, 2021 | -11.72 Mn |
| Sep 30, 2021 | 128.68 Mn |
| Jun 30, 2021 | 195.13 Mn |
| Mar 31, 2021 | 114.65 Mn |